By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Max-Dohrn-Strasse 8-10

Berlin    10589  Germany
Phone: 49-30-726247-0 Fax: 49-30-726247-225



Drug Discovery

Company News
NOXXON Pharma AG Licenses And Assigns Preclinical Spiegelmer Programs To Aptarion 1/4/2017 11:38:08 AM
NOXXON Pharma AG Signs Clinical Immuno-Oncology Collaboration Agreement With Merck & Co. (MRK) To Study Nox-A12 Combined With Keytruda (Pembrolizumab) In Pancreatic And Colorectal Cancer 12/15/2016 10:34:45 AM
NOXXON Pharma AG Releases Its Interim 2016 Results 10/31/2016 9:39:50 AM
NOXXON Pharma AG Demonstrates Synergies Between NOX-A12 And Therapies Working Through T Cells Or NK Cells 10/10/2016 12:17:19 PM
Five Biotechs You Should Know In Berlin 3/11/2016 8:01:57 AM
NOXXON Pharma AG Hosts Key Opinion Leader Symposium 1/20/2016 10:15:12 AM
NOXXON Pharma AG Appoints Aram Mangasarian As CEO 7/14/2015 9:16:46 AM
First Data From NOXXON Pharma AG’s NOX-H94 (Lexaptepid Pegol) Clinical Trial In ESA-Hyporesponsive Dialysis Patients Reported At ERA-EDTA Conference 5/29/2015 9:03:19 AM
NOXXON Pharma AG Release: Nature Communications Publications On The First X-Ray Crystal Structures Of Spiegelmers Bound To Protein Targets 4/23/2015 9:43:02 AM
New Addition To NOXXON Pharma AG Supervisory Board Brings Significant U.S. Public Market Expertise 12/10/2014 8:55:20 AM